Signaling networks in the pathophysiology and treatment of mood disorders

Journal of Psychosomatic Research

Volumn 53, Issue 2, 2002, Pages 687-697

  Gould, Todd D ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Adenylate cyclase; Bipolar disorder; Depression; G proteins; Phosphotidylinositol; Second messenger systems

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; ADENYLATE CYCLASE; AMINE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DESIPRAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; PHOSPHATIDYLINOSITIDE; PROTEIN G; PROTEIN KINASE C; SEROTONIN UPTAKE INHIBITOR; TRANSCRIPTION FACTOR AP 1; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROIC ACID;

BINDING KINETICS; BIPOLAR DISORDER; BRAIN CORTEX; CADAVER; DRUG PROTEIN BINDING; ELECTRIC SHOCK; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; LONG TERM EXPOSURE; MAJOR DEPRESSION; MEDIATOR; MOOD DISORDER; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SECOND MESSENGER; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION;

EID: 0036705074     PISSN: 00223999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3999(02)00426-9     Document Type: Article

References (129)

1. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104(4):569-80.
2. Burmeister M. Basic concepts in the study of diseases with complex genetics. Biol Psychiatry 1999;45(5):522-32.
3. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways. Molecular targets foro lithium's actions. Arch Gen Psychiatry 1995;52(7):531-43.
4. Wang JF, Young LT, Li PP, Warsh JJ. Signal transduction abnormalities in bipolar disorder. In: Young LT, Joffe RT, editors. Bipolar Disorder: Biological Models and Their Clinical Application. New York: Dekker, 1997. pp. 41-79.
5. Jope RS. Anti-bipolar therapy: Mechanism of action of lithium. Mol Psychiatry 1999;4(2):117-28.
6. Spiegel AM. G Proteins, Receptors, and Disease. Totowa (NJ): Humana Press, 1998.
7. Warsh JJ, Young LT, Li PP. Guanine nucleotide binding (G) protein disturbances in bipolar affective disorder. In: Manji HK, Bowden CL, Belmaker RH, editors. Bipolar Medications: Mechanisms of Action. 1st ed. Washington (DC): American Psychiatric Press, 2000. pp. 299-329.
8. Young LT, Li PP, Kish SJ, Siu KP, Kamble A, Hornykiewicz O, Warsh JJ. Cerebral cortex Gs alpha protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem 1993;61(3):980-8.
9. Wang HY, Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 1996;40(7):568-75.
10. Schreiber G, Avissar S, Danon A, Belmaker RH. Hyperfunctional G proteins in mononuclear leukocytes of patients with mania. Biol Psychiatry 1991;29(3):273-80.
11. Young LT, Li PP, Kamble A, Siu KP, Warsh JJ. Mononuclear leukocyte levels of G proteins in depressed patients with bipolar disorder or major depressive disorder. Am J Psychiatry 1994;151(4):594-6.
12. Spleiss O, Van Calker D, Scharer L, Adamovic K, Berger M, Gebicke-Haerter PJ. Abnormal G protein alpha(s) - and alpha(i2) - subunit mRNA expression in bipolar affective disorder. Mol Psychiatry 1998;3(6):512-20.
13. Manji H, Chen G, Potter W, Kosten TR. Guanine nucleotide binding proteins in opioid-dependent patients. Biol Psychiatry 1997;41(2):130-4.
14. Mitchell PB, Manji HK, Chen G, Jolkovsky L, Smith-Jackson E, Denicoff K, et al. High levels of Gs alpha in platelets of euthymic patients with bipolar affective disorder. Am J Psychiatry 1997;154(2):218-23.
15. Avissar S, Nechamkin Y, Roitman G, Schreiber G. Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression. Am J Psychiatry 1997;154(2):211-7.
16. Garcia-Sevilla JA, Walzer C, Busquets X, Escriba PV, Balant L, Guimon J. Density of guanine nucleotide-binding proteins in platelets of patients with major depression: Increased abundance of the G alpha i2 subunit and down-regulation by antidepressant drug treatment. Biol Psychiatry 1997;42(8):704-12.
17. Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 2nd ed. Cambridge (UK): Cambridge Univ. Press, 2000.
18. Chen G, Hasanat KA, Bebchuk JM, Moore GJ, Glitz D, Manji HK. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med 1999;61(5):599-617.
19. Sulser F. Antidepressant treatments and regulation of norepinephrine-receptor-coupled adenylate cyclase systems in brain. Adv Biochem Psychopharmacol 1984;39:249-61.
20. Lesch KP, Manji HK. Signal-transducing G protein and antidepressant drugs: Evidence for modulation of alpha subunit gene expression in rat brain. Biol Psychiatry 1992;32(7):549-79.
21. Okada F, Tokumitsu Y, Ui M. Desensitization of beta-adrenergic receptor-coupled adenylate cyclase in cerebral cortex after in vivo treatment of rats with desipramine. J Neurochem 1986;47(2):454-9.
22. Tiong AH, Richardson JS. Beta-adrenoceptor and post-receptor components show different rates of desensitization to desipramine. Eur J Pharmacol 1990;188(6):411-5.
23. Tsuchiya F, Nanba T, Nomura S. Effects of desipramine administration on receptor adenylate cyclase coupling in rat cerebral cortex. Jpn J Psychiatr Neurol 1988;42:858-60.
24. Yamaoka K, Nanba T, Nomura S. Direct influence of antidepressants on GTP binding protein of adenylate cyclase in cell membranes of the cerebral cortex of rats. J Neural Transm 1988;71(3):165-75.
25. Chen J, Rasenick MM. Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content. J Pharmacol Exp Ther 1995;275(1):509-17.
26. Menkes DB, Rasenick MM, Wheeler MA, Bitensky MW. Guanosine triphosphate activation of brain adenylate cyclase: Enhancement by long-term antidepressant treatment. Science 1983;219(4580):65-7.
27. Ozawa H, Rasenick MM. Coupling of the stimulatory GTP-binding protein Gs to rat synaptic membrane adenylate cyclase is enhanced subsequent to chronic antidepressant treatment. Mol Pharmacol 1989;36(5):803-8.
28. Newman ME, Lerer B. Post-receptor-mediated increases in adenylate cyclase activity after chronic antidepressant treatment: Relationship to receptor desensitization. Eur J Pharmacol 1989;162(2):345-52.
29. Dwivedi Y, Pandey GN. Effects of subchronic administration of antidepressants and anxiolytics on levels of the alpha subunits of G proteins in the rat brain. J Neural Transm 1997;104(6-7):747-60.
30. Emamghoreishi M, Warsh JJ, Sibony D, Li PP. Lack of effect of chronic antidepressant treatment on Gs and Gi alpha-subunit protein and mRNA levels in the rat cerebral cortex. Neuropsychopharmacology 1996;15(3):281-7.
31. Rasenick MM, Chaney KA, Chen J. G protein-mediated signal transduction as a target of antidepressant and antibipolar drug action: Evidence from model systems. J Clin Psychiatry 1996;57(Suppl. 13):49-55 (discussion 56-8).
32. Casebolt TL, Li XH, Jope RS. Alpha-1 adrenergic receptor binding and adrenergic-stimulated cyclic AMP production in rat cerebral cortex after chronic lithium treatment. J Neural Transm: Gen Sect 1990;82(3):197-204.
33. Colin SF, Chang HC, Mollner S, Pfeuffer T, Reed RR, Duman RS, Nestler EJ. Chronic lithium regulates the expression of adenylate cyclase and Gi-protein alpha subunit in rat cerebral cortex. Proc Natl Acad Sci USA 1991;88(23):10634-7.
34. Jakobsen SN, Wiborg O. Selective effects of long-term lithium and carbamazepine administration on G-protein subunit expression in rat brain. Brain Res 1998;780(1):46-55.
35. Li PP, Young LT, Tam YK, Sibony D, Warsh JJ. Effects of chronic lithium and carbamazepine treatment on G-protein subunit expression in rat cerebral cortex. Biol Psychiatry 1993;34(3):162-70.
36. Masana MI, Bitran JA, Hsiao JK, Potter WZ. In vivo evidence that lithium inactivates Gi modulation of adenylate cyclase in brain. J Neurochem 1992;59(1):200-5.
37. Ebstein RP, Oppenheim G, Ebstein BS, Amiri Z, Stessman J. The cyclic AMP second messenger system in man: The effects of heredity, hormones, drugs, aluminum, age and disease on signal amplification. Prog Neuropsychopharmacol Biol Psychiatry 1986;10(3-5):323-53.
38. Newman ME, Lerer B, Lichtenberg P, Shapira B. Platelet adenylate cyclase activity in depression and after clomipramine and lithium treatment: Relation to serotonergic function. Psychopharmacology 1992;109(1-2):231-4.
39. Risby ED, Hsiao JK, Manji HK, Bitran J, Moses F, Zhou DF, Potter WZ. The mechanisms of action of lithium: II. Effects on adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects. Arch Gen Psychiatry 1991;48(6):513-24.
40. Ebstein RP, Moscovich D, Zeevi S, Amiri Z, Lerer B. Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: Postreceptor modification of second messenger signal amplification. Psychiatry Res 1987;21(3):221-8.
41. Hsiao JK, Manji HK, Chen GA, Bitran JA, Risby ED, Potter WZ. Lithium administration modulates platelet Gi in humans. Life Sci 1992;50(3):227-33.
42. Lonati-Galligani M, Emrich HM, Raptis C, Pirke KM. Effect of in vivo lithium treatment on (-)isoproterenol-stimulated cAMP accumulation in lymphocytes of healthy subjects and patients with affective psychoses. Pharmacopsychiatry 1989;22(6);241-5.
43. Wang YC, Pandey GN, Mendels J, Frazer A. Effect of lithium on prostaglandin F1-stimulated adenylate cyclase activity of human platelets. Biochem Pharmacol 1974;23(4):845-55.
44. Garcia-Sevilla JA, Guimon J, Garcia-Vallejo P, Fuster MJ. Biochemical and functional evidence of supersensitive platelet alpha 2-adrenoceptors in major affective disorder. Effect of long-term lithium carbonate treatment. Arch Gen Psychiatry 1986;43(1):51-7.
45. Manji HK, Chen G, Shimon H, Hsiao JK, Potter WZ, Belmaker RH. Guanine nucleotide-binding proteins in bipolar affective disorder. Effects of long-term lithium treatment. Arch Gen Psychiatry 1995;52(2):135-44.
46. Kofman O, Li PP, Warsh JJ. Lithium, but not carbamazepine, potentiates hyperactivity induced by intra-accumbens cholera toxin. Pharmacol, Biochem Behav 1998;59(1):191-200.
47. Chen G, Manji HK, Wright CB, Hawver DB, Potter WZ. Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology 1996;15(3):271-80.
48. Ram A, Guedj F, Cravchik A, Weinstein L, Cao Q, Badner JA, Goldin LR, Grisaru N, Manji HK, Belmaker RH, Gershon ES, Gejman PV. No abnormality in the gene for the G protein stimulatory alpha subunit in patients with bipolar disorder. Arch Gen Psychiatry 1997;54(1):44-8.
49. Manji HK, Chen G, Hsiao JK, Masana MI, Moore GJ, Potter WZ. Regulation of signal transduction pathways by mood stabilizing agents: Implications for the pathophysiology and treatment of bipolar affective disorder. In: Manji HK, Bowden CL, Belmaker RH, editors. Bipolar Medications: Mechanisms of Action. 1st ed. Washington (DC): American Psychiatric Press, 2000. pp. 129-77.
50. Li PP, Andreopoulos S, Warsh JJ. Signal transduction abnormalities in bipolar affective disorder. In: Reith MEA, editor. Cerebral Signal Transduction: From First to Fourth Messengers. Totowa (NJ): Humana Press, 2000. pp. 283-312.
51. Daniel PB, Walker WH, Habener JF. Cyclic AMP signaling and gene regulation. Annu Rev Nutr 1998;18:353-83.
52. Walton MR, Dragunow I. Is CREB a key to neuronal survival? Trends Neurosci 2000;23(2):48-53.
53. Mann JJ, Brown RP, Halper JP, Sweeney JA, Kocsis JH, Stokes PE, Bilezikian JP. Reduced sensitivity of lymphocyte beta-adrenergic receptors in patients with endogenous depression and psychomotor agitation. N Engl J Med 1985;313(12):715-20.
54. Siever LJ. Role of noradrenergic mechanisms in the etiology of the affective disorders. In: Meltzer HY, editor. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987. pp. 493-504.
55. Ebstein RP, Lerer B, Shapira B, Shemesh Z, Moscovich DG, Kindler S. Cyclic AMP second-messenger signal amplification in depression. Br J Psychiatry 1988;152:665-9.
56. Halper JP, Brown RP, Sweeney JA, Kocsis JH, Peters A, Mann JJ. Blunted beta-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression. Isoproterenol dose-response studies. Arch Gen Psychiatry 1988;45(3):241-4.
57. Mork A, Geisler A, Hollund P. Effects of lithium on second messenger systems in the brain. Pharmacol Toxicol 1992;71(Suppl. 1):4-17.
58. Extein I, Tallman J, Smith CC, Goodwin FK. Changes in lymphocyte beta-adrenergic receptors in depression and mania. Psychiatry Res 1979;1(2):191-7.
59. Perez J, Tardito D, Mori S, Racagni G, Smeraldi E, Zanardi R. Abnormalities of cAMP signaling in affective disorders: Implication for pathophysiology and treatment. Bipolar Disord 2000;2(1):27-36.
60. 3 H]cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder. J Neurochem 1997;68(1):297-304.
61. Potter WZ, Manji HK. Catecholamines in depression: An update. Clin Chem 1994;40(2):279-87.
62. Siever LJ, Uhde TW, Jimerson DC, Lake CR, Silberman ER, Post RM, Murphy DL. Differential inhibitory noradrenergic responses to clonidine in 25 depressed patients and 25 normal control subjects. Am J Psychiatry 1984;141(6):733-41.
63. Kafka MS, Paul SM. Platelet alpha 2-adrenergic receptors in depression. Arch Gen Psychiatry 1986;43(1):91-5.
64. Charney DS, Heninger GR, Sternberg DE, Hafstad KM, Giddings S, Landis DH. Adrenergic receptor sensitivity in depression. Effects of clonidine in depressed patients and healthy subjects. Arch Gen Psychiatry 1982;39(3):290-4.
65. Pandey GN, Dysken MW, Garver DL, Davis JM. Beta-adrenergic receptor function in affective illness. Am J Psychiatry 1979;136(5):675-8.
66. Healy D, Carney PA, Leonard BE. Monoamine-related markers of depression: Changes following treatment. J Psychiatr Res 1982;17(3):251-60.
67. Wright AF, Crichton DN, Loudon JB, Morten JE, Steel CM. Beta-adrenoceptor binding defects in cell lines from families with manic-depressive disorder. Ann Hum Genet 1984;48(Pt. 3):201-14.
68. Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem 1989;53(5):1644-7.
69. Popoli M, Brunello N, Perez J, Racagni G. Second messenger-regulated protein kinases in the brain: Their functional role and the action of antidepressant drugs. J Neurochem 2000;74(1):21-33.
70. Rasenick MM, Chen J, Ozawa H. Effects of antidepressant treatments on the G protein-adenylyl cyclase axis as the possible basis of therapeutic action. In: Manji HK, Bowden CL, Belmaker RH, editors. Bipolar Medications: Mechanisms of Action. 1st ed. Washington (DC): American Psychiatric Press, 2000. pp. 87-108.
71. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54(7):597-606.
72. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996;16(7):2365-72.
73. Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 1998;352(9142):1754-5.
74. Manji HK, Chen G. Post-receptor signaling pathways in the pathophysiology and treatment of mood disorders. Curr Psychiatry Rep 2000;2(6):479-89.
75. Chen G, Masana MI, Manji HK. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord 2000;2(3 Pt 2):217-36.
76. Masana MI, Bitran JA, Hsiao JK, Mefford IN, Potter WZ. Lithium effects on noradrenergic-linked adenylate cyclase activity in intact rat brain: An in vivo microdialysis study. Brain Res 1991;538(2):333-6.
77. Jope RS. A bimodal model of the mechanism of action of lithium. Mol Psychiatry 1999;4(1):21-5.
78. Andersen PH, Geisler A. Lithium inhibition of forskolin-stimulated adenylate cyclase. Neuropsychobiology 1984;12(1):1-3.
79. Geisler A, Klysner R, Andersen PH. Influence of lithium in vitro and in vivo on the catecholamine-sensitive cerebral adenylate cyclase systems. Acta Pharmacol Toxicol (Copenh) 1985;56(Suppl. 1):80-97.
80. Mork A, Geisler A. Mode of action of lithium on the catalytic unit of adenylate cyclase from rat brain. Pharmacol Toxicol 1987;60(4):241-8.
81. Mork A, Geisler A. The effects of lithium in vitro and ex vivo on adenylate cyclase in brain are exerted by distinct mechanisms. Neuropharmacology 1989;28(3):307-11.
82. Newman ME, Belmaker RH. Effects of lithium in vitro and ex vivo on components of the adenylate cyclase system in membranes from the cerebral cortex of the rat. Neuropharmacology 1987;26(2-3):211-7.
83. Post RM, Ballenger JC, Uhde TW, Bunney WEJ. Efficacy of carbamazepine in manic-depressive illness: Implications of underlying mechanisms. In: Post RM, Ballenger JC, editors. Neurobiology of Mood Disorders. Baltimore: Williams and Wilkins, 1984. pp. 777-816.
84. Palmer GC, Jones DJ, Medina MA, Stavinoha WB. Anticonvulsant drug actions on in vitro and in vivo levelsof cyclic AMP in the mouse brain. Epilepsia 1979;20(2):95-104.
85. Palmer GC. Interactions of antiepileptic drugs on adenylate cyclase and phosphodiesterases in rat and mouse cerebrum. Exp Neurol 1979;63(2):322-35.
86. Van Calker D, Steber R, Klotz KN, Greil W. Carbamazepine distinguishes between adenosine receptors that mediate different second messenger responses. Eur J Pharmacol 1991;206(4):285-90.
87. Elphick M, Taghavi Z, Powell T, Godfrey PP. Chronic carbamazepine down-regulates adenosine A2 receptors: Studies with the putative selective adenosine antagonists PD115,199 and PD116,948. Psychopharmacology 1990;100(4):522-9.
88. Chen G, Pan B, Hawver DB, Wright CB, Potter WZ, Manji HK. Attenuation of cyclic AMP production by carbamazepine. J Neurochem 1996;67(5):2079-86.
89. Majerus PW. Inositol phosphate biochemistry. Annu Rev Biochem 1992;61:225-50.
90. Kanashiro CA, Khalil RA. Signal transduction by protein kinase C in mammalian cells. Clin Exp Pharmacol Physiol 1998;25(12):974-85.
91. Aderem A. The MARCKS brothers: A family of protein kinase C substrates. Cell 1992;71(5):713-6.
92. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258(5082):607-14.
93. Soderling TR. CaM-kinases: Modulators of synaptic plasticity. Curr Opin Neurobiol 2000;10(3):375-80.
94. 2+ homeostasis. Prog Neurobiol 1991;37(3):255-85.
95. Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JE. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry 1997;154(8):1148-50.
96. Mathews R, Li PP, Young LT, Kish SJ, Warsh JJ. Increased G alpha q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder. Biol Psychiatry 1997;41(6):649-56.
97. Jope RS, Song L, Li PP, Young LT, Kish SJ, Pacheco MA, Warsh JJ. The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. J Neurochem 1996;66(6):2402-9.
98. Subhash MN, Jagadeesh S. Imipramine-induced changes in 5-HT2 receptor sites and inositoltrisphosphate levels in rat brain. Neurochem Res 1997;22(9):1095-9.
99. Allison JH, Stewart MA. Reduced brain inositol in lithium-treated rats. Nat New Biol 1971;233(43):267-8.
100. Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 1980;255(22):10896-901.
101. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: A unifying hypothesis. Cell 1989;59(3):411-9.
102. Jope RS, Williams MB. Lithium and brain signal transduction systems. Biochem Pharmacol 1994;47(3):429-41.
103. Pontzer NJ, Crews FT. Desensitization of muscarinic stimulated hippocampal cell firing is related to phosphoinositide hydrolysis and inhibited by lithium. J Pharmacol Exp Ther 1990;253(3):921-9.
104. Kofman O, Belmaker RH. Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry 1993;34(12):839-52.
105. Godfrey PP. Potentiation by lithium of CMP-phosphatidate formation in carbachol-stimulated rat cerebral-cortical slices and its reversal by myo-inositol. Biochem J 1989;258(2):621-4.
106. Tricklebank MD, Singh L, Jackson A, Oles RJ. Evidence that a proconvulsant action of lithium is mediated by inhibition of myo-inositol phosphatase in mouse brain. Brain Res 1991;558(1):145-8.
107. Moore GJ, Bebchuk JM, Parrish JK, Faulk MW, Arfken CL, Strahl-Bevacqua J, Manji HK. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry 1999;156(12):1902-8.
108. Lenox RH, Manji HK. Lithium. In: Schatzberg AF, Nemeroff CB, editors. The American Psychiatric Press Textbook of Psychopharmacology. 2nd ed. Washington (DC): American Psychiatric Press, 1998. pp. 379-429.
109. Stabel S, Parker PJ. Protein kinase C. Pharmacol Ther 1991;51(1):71-95.
110. Huang KP. The mechanism of protein kinase C activation. Trends Neurosci 1989;12(11):425-32.
111. Manji HK, Chen G, Hsiao JK, Risby ED, Masana MI, Potter WZ. Regulation of signal transduction pathways by mood-stabilizing agents: Implictions for the delayed onset of therapeutic efficacy. J Clin Psychiatry 1996;57(Suppl. 13):34-46 (discussion 47-8).
112. Wang HY, Friedman E. Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology 1989;99(2):213-8.
113. Robinson PJ. The role of protein kinase C and its neuronal substrates dephosphin, B-50, and MARCKS in neurotransmitter release. Mol Neurobiol 1991;5(2-4):87-130.
114. Lenox RH, Watson DG, Patel J, Ellis J. Chroinic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992;570(1-2):333-40.
115. Manji HK, Etcheberrigaray R, Chen G, Olds JL. Lithium decreases membrane-associated protein kinase C in hippocampus: Selectivity for the alpha isozyme. J Neurochem 1993;61(6):2303-10.
116. Li X, Jope RS. Selective inhibition of the expression of signal transduction proteins by lithium in nerve growth factor-differentiated PC12 cells. J Neurochem 1995;65(6):2500-8.
117. Watson DG, Watterson JM, Lenox RH. Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: A property of protein kinase C-mediated mood stabilizers. J Pharmacol Exp Ther 1998;285(1):307-16.
118. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 1994;63(6):2361-2364.
119. Hughes P, Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol Rev 1995;47(1):133-78.
120. Chen G, Yuan PX, Jiang YM, Huangn LD, Manji HK. Valproate robustly enhances AP-1 mediated gene expression. Brain Res Mol Brain Res 1999;64(1):52-8.
121. Yuan PX, Chen G, Huang LD, Manji HK. Lithium stimulates gene expression through the AP-1 transcription factor pathway. Brain Res Mol Brain Res 1998;58(1-2):225-230.
122. Chen G, Yuan PX, Jiang YM, Huang LD, Manji HK. Lithium increases tyrosine hydroxylase levels both in vivo and in vitro. J Neurochem 1998;70(4):1768-71.
123. Robertson ED, English JD, Adams JP, Selcher JC, Kondratick C, Sweatt JD. The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus. J Neurosci 1999;19(11):4337-48.
124. Kandel ER. A new intellectual framework for psychiatry. Am J Psychiatry 1998;155(4):457-69.
125. Vawter MP, Freed WJ, Kleinman JE. Neuropathology of bipolar disorder. Biol Psychiatry 2000;48(6):486-504.
126. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: Implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000;48(8):740-54.
127. Yuan PX Huong LD, Jiang YM, Gutkind JS, Manji HK, Chenl G. The mood-stabilizer valporic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001;19;19.
128. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizer valproate inhibitis the activity of glycogen synthase kinase-3. J Neurochem 1999;72(3):1327-30.
129. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;25:25.